Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Ingresos totales | ₹104.8B | ₹93.2B | ₹78.0B | ₹76.7B |
| Beneficio bruto | ₹62.0B | ₹54.5B | ₹45.3B | ₹44.9B |
| Ingresos operativos (EBIT) | ₹29.8B | ₹25.7B | ₹18.3B | ₹20.3B |
| Ingresos netos | ₹25.7B | ₹21.9B | ₹16.0B | ₹18.2B |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de DIVISLAB. /companies/us/DIVISLAB
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms